^
Association details:
| Biomarker: | CXCR4 mutation |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Excerpt:
...Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0`Number of Participants With Complete Response`Number of Participants With Very Good Partial Response`Number of Participants With Partial Response`Number of Participants With Minor Response`Number of Participants With Stable Disease`Progression Free Survival`Overall Response Rate Among CXCR4 Mutated Participants`Overall Response Rate Among Participants Without CXCR4 Mutations...
Trial ID:
Source:
Title:
PROSPECTIVE PHASE II STUDY OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED WALDENSTROM MACROGLOBULINEMIA (WM)
Published date:
05/17/2018
Excerpt:
We initiated a phase II study to evaluate the safety and efficacy of ven monotherapy in previously treated pts with WM (NCT02677324)….The MYD88L265P mutation was detected in all pts, and CXCR4 mutations in 16 (53%)…. At best response, very good partial response (VGPR) was attained in 5 pts (17%), partial response in 11 (37%), minor response in 8 (27%) and stable disease in 6 (20%), for overall response rate of 80% and major response rate of 53%.
Trial ID:
